Next 10 |
home / stock / aplif / aplif news
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmac...
Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) . Appili is a biopharmaceutical company focused on drug develo...
2024-04-02 08:51:10 ET More on Aditx Therapeutics, Appili Therapeutics, etc. Evofem Biosciences achieves 2023 prelim net product sales of $18.1M to $18.3M Aditxt buys Brain Scientific's portfolio of EEG brain monitoring technologies and devices Financial information ...
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX),...
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED S...
HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publicat...
2024-02-14 08:37:59 ET More on Appili Therapeutics Seeking Alpha’s Quant Rating on Appili Therapeutics Historical earnings data for Appili Therapeutics Financial information for Appili Therapeutics Read the full article on Seeking Alpha For fur...
FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-18...
ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...
Patent coverage provides drug market exclusivity through at least 2039 Pre-IND meeting with the FDA granted to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “...
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc Company Name:
APLIF Stock Symbol:
OTCMKTS Market:
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NE...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmac...
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and...